What is Recombitek West Nile Vaccine?
Recombitek West Nile Vaccine 10 x 1 Dose is recommended for the vaccination of healthy horses as an aid in the prevention of viremia, caused by the West Nile Virus infection.
Who is it for?
Why use it?
- Protect healthy horses from viremia caused by West Nile Virus infection.
- Vaccination may be the only way to protect horses from some disease.
- Recombitek is proven to work fast and last throughout the mosquito season.
- Onset of immunity in just 26 days after the initial dose.
How it works?
After inoculation, the vector does not multiply in the horse, but does express the protective proteins. As a result, these components induce an immune status against West Nile Virus. Safety and immunogenicity of this vaccine have been demonstrated by vaccination and challenge tests in susceptible horses
lyophilized recombinant canarypox vectored West Nile Virus vaccine plus a sterile liquid diluent
How is it sold?
10 x 1ml Vial
What are the side effects?
As with any vaccine, a hypersensitivity reaction may occur, which may require appropriate symptomatic treatment.
What special precautions are there?
For the preparation and administration of the vaccine, use sterile and antiseptic-free and/or disinfectant-free material. Burn container and all unused contents.
Contains gentamicin as a preservative.
What to do if overdose?
In case of anaphylactoid reaction, consult your nearest animal hospital.
How Can I store it?
Store at 2-7°C (35-45°F)
In some instances, transient local swelling may occur at the injection site. As with any vaccine, a hypersensitivity reaction may occur, which may require appropriate symptomatic treatment.
Reconstitute the lyophilized vaccine with accompanying liquid diluent and aseptically inject a 1 ml dose by intramuscular route.
For primary vaccination, revaccinate with a second 1 ml dose of this product 4 to 6 weeks later.
Annual revaccination with a single dose is recommended.
RECOMBITEK® Equine West Nile Virus contains a lyophilized recombinant canarypox vectored West Nile Virus vaccine plus a sterile liquid diluent. A canarypox vector has been modified using recombinant technology to express the desired antigens capable of stimulating a protective immune response to West Nile Virus. After inoculation, the vector does not multiply in the horse, but does express the protective proteins. As a consequence, these components induce an immune status against West Nile Virus. Safety and immunogenicity of this vaccine have been demonstrated by vaccination and challenge tests in susceptible horses.
West Nile Virus
West Nile virus is a disease spread by mosquito. Mosquitoes carry the highest amounts of virus in the early fall, which is why the rate of the disease increases in late August to early September. The risk of disease decreases as the weather becomes colder and mosquitoes die off.
Infection with West Nile Virus does not always lead to signs of illness in people or animals. Horses appear to be a species that is susceptible to infection with the virus. In horses that do become clinically ill, the virus infects the central nervous system and may cause symptoms of encephalitis. Clinical signs of encephalitis in horses may include a general loss of appetite and depression, in addition to any combination of the following signs:
- Weakness of hind limbs
- Paralysis of hind limbs
- impaired vision
- Head pressing A
- Aimless wandering
- Convulsions (seizures)
- Inability to swallow
- Walking in circles H